Identifying extra-nuclear factors that control the production of cannabidiol

识别控制大麻二酚生产的核外因素

• 批准号: 500661-2016
• 负责人: Campbell, Lesley
• 金额: $ 3.5万
• 依托单位: Ryerson University
• 依托单位国家: 加拿大
• 项目类别: Collaborative Research and Development Grants
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=608223
• 关键词: Identifying; extra; nuclear; factors; control

The Trudeau government plans to "legalize, regulate, and restrict access to marijuana". However, safe medicinal use of the pharmaceutical chemicals produced by this plant (cannabinoids and terpenes) must also be rooted in a scientific understanding of best practices. Despite cultivation for millennia, medical marijuana has been largely absent from modern scientific research programs. Therefore claims of therapeutic benefits and knowledge of how to produce the pharmaceutical compounds (cannabinoids) lags behind the legislation that allows medical marijuana use in Canada. This limits companies, like First Access Medical, in their development of industrial scale processes that reliably produce particular cannabinoids from plants. Our research proposes to contribute new knowledge of the molecular entities that control the production of one key cannabinoid, cannabidiol. To this end, we will compare protein and transcribed DNA profiles of marijuana cultivars that produce cannabidiol in high and low quantities. We will also create mathematical models that compare predicted cannabidiol profiles of cultivars with high and low quantities to those created in a careful plant breeding program. This new knowledge will allow FAM to sell new products, increase their market competitiveness and maintain high quality and standardized drugs for patients, predict practical yields, and evaluate clinical applications. This research will accelerate intellectual property development and thus create a new revenue stream for FAM. The capacity to predictably produce cannabinoids, the active ingredients in therapeutic products, could have profound medicinal and economic importance to Canada.

特鲁多政府计划“将大麻合法化、监管和限制获取大麻”。然而，这种植物生产的药用化学品（大麻素和萜烯）的安全医疗用途也必须植根于对最佳做法的科学理解。尽管种植了几千年，但医用大麻在现代科学研究项目中基本上是缺席的。因此，关于治疗益处和如何生产药物化合物（大麻素）的知识的主张落后于允许在加拿大使用医用大麻的立法。这限制了像First Access Medical这样的公司开发工业规模流程，从植物中可靠地生产特定的大麻素。我们的研究旨在为控制一种关键大麻素，大麻二酚生产的分子实体提供新的知识。为此，我们将比较产生高量和低量大麻二酚的大麻品种的蛋白质和转录DNA谱。我们还将创建数学模型，将预测的大麻二酚含量高和低的品种与精心的植物育种计划中创建的品种进行比较。这些新知识将使FAM能够销售新产品，提高其市场竞争力，并为患者保持高质量和标准化的药物，预测实际产量，并评估临床应用。这项研究将加速知识产权的开发，从而为FAM创造新的收入来源。可预见的生产大麻素的能力，治疗产品中的活性成分，可能对加拿大具有深远的医学和经济重要性。